Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage regenerative medicine company focused on developing off-the-shelf bioengineered human acellular vessels for vascular repair and reconstruction. The company became publicly listed in 2021 through its merger with Alpha Healthcare Acquisition Corp., a blank-check vehicle sponsored by Alpha Healthcare Acquisition Holdings LLC, which completed its IPO in 2020. Humacyte operates in the biotechnology and medical device sector and has been advancing its flagship HAV platform through regulatory and clinical pathways following the de-SPAC combination. The company filed an 8-K with the SEC on August 12, 2026, accession number 0001104659-26-094440. For full filing details, corporate history, and real-time SPAC analytics on HUMA and hundreds of other transactions, sign up for complete access at SpacDesk.